Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FOLLITROPIN FOR PEPTIDE MAPPING AND GLYCAN ANALYSIS CRS (0.5

FOLLITROPIN FOR PEPTIDE MAPPING AND GLYCAN ANALYSIS CRS (0.5

NA

DISCOVER
TRIBENOSIDE IMPURITY D CRS (100 MG)

TRIBENOSIDE IMPURITY D CRS (100 MG)

103-50-4

DISCOVER
FOLLITROPIN CRS (0.2 MG)

FOLLITROPIN CRS (0.2 MG)

NA

DISCOVER
PREDNICARBATE FOR SYSTEM SUITABILITY A CRS (10 MG)

PREDNICARBATE FOR SYSTEM SUITABILITY A CRS (10 MG)

73771-04-7

DISCOVER
PANCREAS  POWDER  (LIPASE) BRP (2000 MG)

PANCREAS POWDER (LIPASE) BRP (2000 MG)

8049-47-6

DISCOVER
PANCREAS  POWDER  (AMYLASE) BRP (2000 MG)

PANCREAS POWDER (AMYLASE) BRP (2000 MG)

8049-47-6

DISCOVER
ETHYLCELLULOSE CRS (100 MG)

ETHYLCELLULOSE CRS (100 MG)

9004-57-3

DISCOVER
BRIMONIDINE FOR SYSTEM SUITABILITY CRS (1.3 MG)

BRIMONIDINE FOR SYSTEM SUITABILITY CRS (1.3 MG)

NA

DISCOVER
DICLOFENAC FOR SYSTEM SUITABILITY CRS (1 MG)

DICLOFENAC FOR SYSTEM SUITABILITY CRS (1 MG)

15307-79-6

DISCOVER
LEVOCABASTINE FOR SYSTEM SUITABILITY 1 CRS (5.028 MG)

LEVOCABASTINE FOR SYSTEM SUITABILITY 1 CRS (5.028 MG)

79547-78-7

DISCOVER
LEVOCABASTINE FOR SYSTEM SUITABILITY 2 CRS (5.005 MG)

LEVOCABASTINE FOR SYSTEM SUITABILITY 2 CRS (5.005 MG)

79547-78-7

DISCOVER
CHLORMADINONE ACETATE FOR SYSTEM SUITABILITY CRS (10 MG)

CHLORMADINONE ACETATE FOR SYSTEM SUITABILITY CRS (10 MG)

302-22-7

DISCOVER